Search research articles
Contact Us
Filters
Showing results (31-40 of 306) with videos related to
Page
of 31
Sort By:
Seminars in Hematology
|
January 9, 2008
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes
Elizabeth A Griffiths, Steven D Gore
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2014
New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach
Amer M Zeidan, Steven D Gore
The Journal of Burn Care & Rehabilitation
|
January 1, 1995
Evaluation of calcium alginate for skin graft donor sites
D Bettinger, D Gore, Y Humphries
Seminars in Oncology
|
March 12, 1999
Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia
W J Edenfield, S D Gore
Endocrinology
|
June 1, 1984
Alteration of transmembrane sodium and potassium gradients inhibits the action of luteinizing hormone in the luteal cell
S D Gore, H R Behrman
Expert Opinion on Investigational Drugs
|
November 28, 2000
Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors
S D Gore, M A Carducci
Expert Opinion on Emerging Drugs
|
August 9, 2005
Emerging drugs for the treatment of myelodysplastic syndrome
Philip J Nivatpumin, Steven D Gore
Oncology (Williston Park, N.Y.)
|
July 2, 2011
Myelodysplastic syndromes: where do we go from here?
Hetty E Carraway, Steven D Gore
Leukemia & Lymphoma
|
February 2, 2022
Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis
Rory M Shallis, Steven D Gore
Nature Reviews. Drug Discovery
|
November 23, 2006
Decitabine
Steven D Gore, Carole Jones, Peter Kirkpatrick
Page
of 31
Search research articles
Search
Showing results (31-40 of 306) with videos related to
Sort By:
Page
of 31
Seminars in Hematology
|
January 9, 2008
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes
Elizabeth A Griffiths, Steven D Gore
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2014
New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach
Amer M Zeidan, Steven D Gore
The Journal of Burn Care & Rehabilitation
|
January 1, 1995
Evaluation of calcium alginate for skin graft donor sites
D Bettinger, D Gore, Y Humphries
Seminars in Oncology
|
March 12, 1999
Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia
W J Edenfield, S D Gore
Endocrinology
|
June 1, 1984
Alteration of transmembrane sodium and potassium gradients inhibits the action of luteinizing hormone in the luteal cell
S D Gore, H R Behrman
Expert Opinion on Investigational Drugs
|
November 28, 2000
Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors
S D Gore, M A Carducci
Expert Opinion on Emerging Drugs
|
August 9, 2005
Emerging drugs for the treatment of myelodysplastic syndrome
Philip J Nivatpumin, Steven D Gore
Oncology (Williston Park, N.Y.)
|
July 2, 2011
Myelodysplastic syndromes: where do we go from here?
Hetty E Carraway, Steven D Gore
Leukemia & Lymphoma
|
February 2, 2022
Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis
Rory M Shallis, Steven D Gore
Nature Reviews. Drug Discovery
|
November 23, 2006
Decitabine
Steven D Gore, Carole Jones, Peter Kirkpatrick
Page
of 31